Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lifecare AS ( (DE:LFC0) ) has shared an update.
Lifecare ASA has successfully completed radio frequency compliance testing for its implantable Continuous Glucose Monitoring (CGM) system, marking a significant milestone in its regulatory process. This achievement confirms the device’s safety and performance, paving the way for human clinical trials and advancing the company’s path toward CE-marking and a commercial launch in 2027, thereby enhancing confidence in its market potential.
More about Lifecare AS
Lifecare ASA is a MedTech company specializing in the development of next-generation Continuous Glucose Monitoring (CGM) systems for diabetes management. The company focuses on using osmotic pressure as a sensing principle to monitor various body analytes, aiming to revolutionize diabetes care with their proprietary implant technology.
Average Trading Volume: 49,389
Current Market Cap: NOK106.4M
Learn more about LFC0 stock on TipRanks’ Stock Analysis page.